国产氯吡格雷对PCI术后患者的长期疗效及安全性观察

Observation of the enduring efficacy and safety of domestic Clopidogrel Hydrogen Shlfate Tablets applied to patients after PCI

目的观察国产氯吡格雷对PCI术后患者的长期疗效及安全性。方法将257例行PCI术患者随机分为2组,其中国产氯吡格雷组129例,进口氯吡格雷组128例。两治疗组PCI术前服用氯吡格雷75mg/d,并于术前至少6h顿服氯吡格雷300mg,两组PCI术后继续服用氯吡格雷75mg/d,观察术后12个月内MACE及主要不良反应。结果国产氯吡格雷对PCI术后12个月内MACE及主要不良反应无统计学意义。结论国产氯吡格雷对PCI术后患者的长期疗效是安全、有效的,经济便宜,值得临床推广。

Objective To observe the long-term effectiveness and safety of domestic clopidogrel （Talcom） on patients after percutaneous coronary intervention （PCI）. Methods A total of 257 patients were randomly divided into two groups after PCI, including domestic clopidogrel group （ n = 129 ） and imported clopidogrel （Plavix） group （n = 128）, 300 mg of clopidogrel were given 6 hours prior to PCI respectively followed by 75 mg daily, Major adverse cardiac events （MACE） and adverse effects were observed in 12 months after PCI. Results There was no statistic significance in MACE and adverse effect in 12 months after PCI. Conclusion Domestic clopidogrel may be effective and safe for patients after PCI, which is economic and worthy of further clinical application.